List view / Grid view
An Asia flow chemistry system from Syrris is helping to streamline biocatalysis reactions for researchers at the Biocatalysis and Organic Synthesis Group at the Chemistry Institute of the Federal University of Rio de Janeiro...
Novel regimen enables physicians to fully dose up to two months of Aristada treatment on day one...
Evidence suggests the human papillomavirus plays a role in the development of some types of this skin cancer...
A study shows low-dose aspirin may aid removal of harmful amyloid plaque in the brain...
A diabetes drug suggests a potential therapy for idiopathic pulmonary fibrosis...
Bioprocessing professionals in search of a technology that could revolutionise their downstream processing, are invited to attend a Lunch and Learn event from Watson-Marlow Fluid Technology Group (WMTFG), in association with The National Institute for Bioprocessing Research and Training (NIBRT)...
Testing could lead to extension of life through improved clinical decision-making by identifying patients who need to switch from targeted hormonal therapy to chemotherapy...
Higher daily doses of rifampin, a cornerstone of tuberculosis treatment, were shown to kill more TB bacteria in sputum cultures without increasing the adverse effects of treatment, according to a recent randomised controlled trial.
Researchers believe the combination with established treatment could improve outcomes in prostate cancer...
Leveraging nanoparticles and digital health technology, BWH investigators develop rapid, deployable, low-cost diagnostic test for Zika virus
The FDA has approved Epidiolex oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy...
A combination of mTOR inhibitors and Phenformin leads to an increase in overall survival...
bioMérieux, a world leader in the field of industrial microbiological control, announces the launch of ENDOZYME® II GO, a new endotoxin test in the bioMérieux ENDONEXT™ range of recombinant horseshoe crab Factor C (rFC) assays.
Pivot Pharmaceuticals Inc. is to begin human clinical trials of PVT-005, the pharmaceutical drug candidate for the treatment of HSDD...
Researchers at Children's Hospital Los Angeles and the University of Southern California have demonstrated the feasibility of implanting a micropacemaker system in the pericardial sac surrounding the heart – a breakthrough that may open up new cardiac pacing options for children and adults.
